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Introduction
Axons of the central nervous system (CNS) demonstrate no functionally signifi cant regeneration after injury, in contrast to those of the peripheral nervous system, which regenerate vigorously, leading often to complete functional recovery. This lack of regeneration generally results in partial disability or complete paralysis after a CNS injury. However, some adult CNS axons can grow through a peripheral nerve graft (David and Aguayo, 1981) , suggesting that the local glial environment of the adult CNS is a major cause of the lack of regeneration. So far, three major inhibitors-Nogo, myelin-associated glycoprotein (MAG), and oligodendrocyte-myelin glycoprotein (OMgp)-expressed by oligodendrocytes and myelinated fi ber tracts have been identifi ed. Interestingly, all these inhibitors were found to bind to the Nogo receptor (NgR) in complex with p75 or TROY, members of the TNF receptor family, suggesting that they have common signaling pathways (Teng and Tang, 2005) .
However, some reports suggest that inhibition of these molecules alone is insuffi cient for regeneration after CNS injury (Teng and Tang, 2005) . MAG knockout mice exhibited little or no enhancement of axonal regeneration in the spinal cord. There seems to be some controversy concerning Nogo knockout mice and NgR-defi cient mice. Neither depletion of functional p75 nor administration of a soluble p75-Fc at the lesion site promoted regeneration of the injured spinal cord. These fi ndings prompted us to search for new inhibitors.
Repulsive guidance molecule (RGM), which has been reported as the 33-kD mass tectum repellent in chick, induces the collapse of temporal but not nasal growth cones and guides temporal retinal axons in vitro (Stahl et al. 1990; Muller et al., 1996; Monnier et al., 2002) . RGM binds to neogenin, identifi ed as a netrin-1 receptor and homologue of DCC (deleted in colorectal cancer), mediating its repulsive activity toward retinal axons (Rajagopalan et al., 2004) . During chick development, neogenin functions as a dependence receptor, inducing cell death in the absence of RGM (Matsunaga et al., 2004) . Three mouse proteins, homologous to chick RGM, termed mRGMa, -b, and -c (Niederkofl er et al., 2004; Oldekamp et al., 2004; Schmidtmer and Engelkamp, 2004) have been reported. Mouse RGMa is highly homologous (80% identity) to chick RGM. Functional studies in RGMa mutant mice revealed the role of RGMa in controlling cephalic neural tube closure (Niederkofl er et al., 2004) .
epulsive guidance molecule (RGM) is a protein implicated in both axonal guidance and neural tube closure. We report RGMa as a potent inhibitor of axon regeneration in the adult central nervous system (CNS). RGMa inhibits mammalian CNS neurite outgrowth by a mechanism dependent on the activation of the RhoARho kinase pathway. RGMa expression is observed in oligodendrocytes, myelinated fi bers, and neurons of the adult rat spinal cord and is induced around the injury site after spinal cord injury. We developed an antibody to RGMa that effi ciently blocks the effect of RGMa in vitro. Intrathecal administration of the antibody to rats with thoracic spinal cord hemisection results in signifi cant axonal growth of the corticospinal tract and improves functional recovery. Thus, RGMa plays an important role in limiting axonal regeneration after CNS injury and the RGMa antibody offers a possible therapeutic agent in clinical conditions characterized by a failure of CNS regeneration.
We reported that up-regulation of RGMa was observed at the lesioned or damaged site after spinal cord injury (SCI) in rats (Schwab et al., 2005a) and focal cerebral ischemia and traumatic brain injury in humans (Schwab et al., 2005b) . In addition, neogenin and other netrin-1 receptors are constitutively expressed by neurons and glial cells in the adult rat spinal cord (Manitt et al., 2004) . These fi ndings prompted us to hypothesize that RGMa may play a role in inhibiting axonal regeneration after CNS injury. In this study, we show that RGMa inhibits neurite outgrowth in postnatal cerebellar neurons in vitro. RGMa expression is induced after SCI in rats at the lesion site, in the developing scar tissue, and on the myelinated fi ber tracts. Local administration of a neutralizing antibody to RGMa signifi cantly facilitates locomotor improvement and axon regeneration after SCI.
Results

RGMa inhibits neurite outgrowth by a mechanism dependent on the activation of the RhoA-Rho kinase pathway
We fi rst asked whether RGM contributes to the inhibition of mammalian CNS neurite outgrowth in vitro. Cerebellar granule neurons were used because they express the receptor for RGMa (Fig. S1 , available at http://www.jcb.org/cgi/content/full/ jcb.200508143/DC1). We cultured cerebellar granule neurons from postnatal rats (postnatal days 7-9) on confl uent monolayers of either CHO cells expressing rat RGMa (RGMa-CHO cells) or control CHO cells for 24 h and assessed the neurite outgrowth rate (the coculture assay). Neurite outgrowth was Figure 1 . Effects of membrane bound/diffusible RGMa on neurons. (A) The membrane bound form of RGMa inhibits neurite outgrowth by a Rho-kinasedependent mechanism. The cerebellar neurons were cultured for 24 h on control CHO cells (control) or RGMa-CHO cells (RGMa) in the presence or absence of 10 μM Y27632. (B) Mean length of the longest neurite per neuron. *, P < 0.01 compared with the control; **, P < 0.01 compared with RGMa (t test). (C) RGMa activates RhoA. The cerebellar neurons were treated for 10 min with conditioned media, derived from PI-PLC treatment of control CHO or RGMa-CHO cells. The active fraction of RhoA along with total RhoA was detected by Western blot. (D) Immunostaining of the supernatant from control/RGMa CHO cells treated with or without PI-PLC. The protein was detected by an anti-HA antibody. Coomassie staining was performed for the same samples. (E) The soluble form of RGMa inhibits neurite outgrowth. Neurons were cultured on PLL-coated chamber slides for 12 h in the conditioned media from untreated control CHO cells, PI-PLC-treated control CHO cells, untreated RGMa-CHO cells, or PI-PLC-treated RGMa-CHO cells. (F) Mean length of the longest neurite per neuron. *, P < 0.01 compared with the control CHO PI-PLC(+) (t test). (G) PI-PLC treatment reverses the inhibitory effect of RGMa-CHO cells. Neurons were cultured for 24 h on control/RGMa CHO cells pretreated with or without PI-PLC. (H) Mean length of the longest neurite per neuron. *, P < 0.01 compared with the control CHO PI-PLC(−); **, P < 0.01 compared with RGMa-CHO PI-PLC(−) (t test). There is no signifi cant difference between the control CHO PI-PLC(+) and RGMa-CHO PI-PLC(+). (I-L) RGMa inhibits neurite outgrowth by an NgR-independent mechanism. (I) The cerebellar neurons were cultured for 24 h on control/RGMa CHO cells in the presence or absence of 1 μM NEP1-40. (J) Mean length of the longest neurite per neuron. *, P < 0.01 compared with the control; **, P < 0.01 compared with the control + NEP1-40 (t test). There is no signifi cant difference between RGMa and RGMa+NEP1-40. (K) The neurons were cultured on PLL-coated chamber slides for 24 h in the conditioned media from PI-PLC-treated control/ RGMa CHO cells in the presence or absence of 1 μM NEP1-40. (L) Mean length of the longest neurite per neuron. *, P < 0.01 compared with the control; **, P < 0.01 compared with the control + NEP1-40 (t test). There is no signifi cant difference between RGMa and RGMa + NEP1-40. Data are represented as the mean ± SEM of three independent experiments. signifi cantly inhibited when grown on RGMa-CHO cells (Fig. 1,  A and B) . To explore the signal transduction mechanism involved in the inhibition of neurite outgrowth, we assessed whether the neuronal effects of RGMa are dependent on the small GTPase RhoA or its downstream effector, the Rho-associated serine/threonine kinase (Rho kinase). We cultured the neurons on RGMa-CHO cells in the presence of 10 μM Y27632, a specifi c inhibitor of Rho kinase (Uehata et al., 1997) , for 24 h and observed that the inhibitory activity of RGMa was abolished by Y27632 (Fig. 1, A and B) . To directly assess whether RhoA is involved in the signal transduction of RGMa, the activity of RhoA was determined using the RhoA binding domain of the effector protein, Rhotekin (Ren et al., 1999;  Fig. 1 C) . The assay revealed that within 10 min after the addition of soluble RGMa (see the following paragraph), extracts of the cells contained increased amounts of GTP-RhoA compared with those of the control cells. These results suggest that RGMa inhibits neurite outgrowth by a mechanism dependent on the activation of the RhoA-Rho kinase pathway.
Because rat RGMa, as well as chick RGM (Monnier et al., 2002) , may be a glycosylphosphatidylinositol-linked protein that anchors to the cell surface, we examined whether the soluble form of RGMa shows the same activity. The RGMa-CHO or control CHO cells were treated with phosphatidylinositolspecifi c PLC (PI-PLC). RGMa was released into the supernatant from the RGMa-CHO cells by the treatment as assessed by immunodetection on Western blots (Fig. 1 D) . We then cultured the neurons with the supernatant for 12 h and measured the neurite length (Fig. 1 , E and F; the soluble RGMa assay). There was no signifi cant difference in the neurite length between neurons cultured in conditioned media from PI-PLC-treated control CHO cells and those treated with media from nontreated control CHO cells, demonstrating that PI-PLC itself had no effect on neurite outgrowth. Neurite outgrowth was signifi cantly inhibited when the neurons were cultured in conditioned media from PI-PLC-treated RGMa-CHO cells, demonstrating that the soluble form of RGMa inhibited neurite outgrowth. Next, we cultured the neurons on PI-PLC-treated RGMa-CHO cells for 24 h and observed that the inhibitory activity of RGMa was significantly reduced (Fig. 1, G and H) , suggesting that RGMa was released from the cells by the PI-PLC treatment.
The fi ndings that RGMa activates RhoA and inhibits neurite outgrowth prompted us to examine whether RGMa signals via the NgR. To determine whether RGMa binds to the NgR, the neurons were cultured for 24 h on RGMa-CHO cells (Fig. 1,  I and J) or with soluble RGMa (Fig. 1 , K and L) in the presence or absence of 1 μM NEP1-40 (GrandPre et al., 2002) . The inhibitory effect of RGMa was not signifi cantly altered by NEP1-40, suggesting that RGMa inhibits neurite outgrowth by an NgRindependent mechanism.
RGMa protein is expressed in purifi ed CNS myelin and adult rat spinal cord
To examine the protein expression of RGMa in the adult CNS, antisera were generated against a synthetic rat RGMa-specifi c peptide and affi nity purifi ed. As shown in the anti-HA antibody as well as the anti-RGMa antibody recognized a protein with an approximate molecular mass of 33 kD in the lysates from the CHO cells expressing HA-tagged RGMa (RGMa-CHO cells). Identical patterns of immunostaining were observed with the anti-HA and anti-RGMa antibody in the RGMa-CHO cells. The anti-RGMa antibody detected a 33-kD band in the purifi ed CNS myelin (Fig. 2 A) and lysates of the rat spinal cord (Fig. 2 F) . In addition, we confi rmed that the anti-RGMa antibody does not cross-react with chondroitin sulfate proteoglycans (CSPGs) or MAG (Fig. 2 A) . The specifi city of the antibody was further confi rmed by its depleted immunoreactivity with excess antigen peptide (residues 309-322 of rat RGMa) in the injured and noninjured adult spinal cords (Fig. S2 B) .
We then performed immunohistochemistry to investigate the distribution pattern of RGMa protein in the adult rat spinal cord. RGMa expression was found in both white and gray matter (Fig. 2 B) . Double staining using anti-RGMa and antimyelin/oligodendrocyte-specifi c protein (MOSP) antibodies (Dyer et al., 1991; Beck et al., 1995) showed that RGMa was expressed in oligodendrocyte cell bodies and their processes in the white matter (Fig. 2 D) . In addition, RGMa was localized to the somata of neuron-specifi c β tubulin III protein (Tuj1)-positive neurons in the gray matter but not to the axons of these cells (Fig. 2 E) . Double immunostaining with the anti-RGMa antibody and the antibody against the glial fi brillary acidic protein (GFAP), an astrocyte marker, showed no colocalization, demonstrating that RGMa is not present in astrocytes (Fig. 2 C) . Collectively, RGMa is expressed by neurons and oligodendrocytes, and its expression pattern in the spinal cord is similar to that of Nogo or OMgp (Hunt et al., 2002) .
Expression of RGMa is up-regulated after SCI
As our data demonstrate that RGMa inhibits postnatal CNS neurons in vitro ( Fig. 1 ) and that RGMa is expressed by neurons and oligodendrocytes in the adult spinal cord (Fig. 2 , B-E), RGMa may play a role in inhibiting axonal regeneration after CNS injury. To test this hypothesis, we examined RGMa expression after SCI. Western blot analysis revealed an increased RGMa expression in the spinal cord 7 d after injury (Fig. 2 F) . We performed immunohistochemistry on fresh frozen sections obtained at 6 h and 1, 3, and 7 d after dorsal hemisection of the thoracic spinal cord in rats. RGMa expression was induced around the injury site after the surgery and was detected in the lesion epicenter (Fig. 2 , G and H) and the white matter rostral (Fig. 2 , G and I) and caudal (not depicted) to the lesion site. In the epicenter area ( Fig. 2 H) , the tissue structure appeared normal 6 h after injury. Subsequently, when degenerative changes began to be observed 1-3 d after injury, immunoreactivity for RGMa was found in the cells around the lesion site and in areas of aberrant extracellular matrix. This extracellular immunoreactivity may be attributable to the degeneration of RGMa-expressing cells or to the secretion of RGMa by RGMa-positive cells. In the white matter adjacent to the epicenter area ( Fig. 2 I) , the number of RGMa-immunopositive cells and the intensity of immunoreactivity remained almost unaltered after 6 h. However, 1-3 d after injury, the number of RGMa-positive cells had progressively increased. At 7 d after injury, there was a signifi cant Mean length of the longest neurite per neuron. *, P < 0.01 compared with the control; **, P < 0.01 compared with the control + control IgG; ***, P < 0.01 compared with RGMa (t test). There is no signifi cant difference between the control + anti-RGMa and RGMa + anti-RGMa. (C) Neurons were cultured on PLL-coated chamber slides for 24 h in conditioned media from PI-PLC-treated control CHO/RGMa CHO cells supplemented with or without 10 μg/ml of the control IgG or anti-RGMa antibody. (D) Mean length of the longest neurite per neuron. *, P < 0.01 compared with the control; **, P < 0.01 compared with the control + control IgG; ***, P < 0.01 compared with RGMa (t test). There is no signifi cant difference between the control + anti-RGMa and RGMa + anti-RGMa. (E) Neurons were cultured on PLL-coated (control) or PLL + myelin-coated (myelin) chamber slides for 24 h in the presence or absence of 10 μg/ml of the anti-RGMa antibody. (F) Mean length of the longest neurite per neuron. *, P < 0.01 compared with the control; **, P < 0.01 compared with myelin; ***, P < 0.01 compared with the control + anti-RGMa. (G) Immunodepletion of purifi ed CNS myelin. CNS myelin, depleted myelin, and the protein A beads after immunodepletion were blotted with the anti-RGMa antibody. (H) Neurons were cultured on PLL-coated (control), PLL + myelin-coated (myelin), and PLL + depleted myelin-coated (d-Myelin) chamber slides for 24 h. (I) Mean length of the longest neurite per neuron. *, P < 0.01 compared with the control; **, P < 0.03 compared with myelin; ***, P < 0.04 compared with the control. Data are represented as the mean ± SEM of three independent experiments. increase in the number of RGMa-immunopositive cells in the epicenter area.
We performed a double-labeling experiment 7 d after the injury to characterize the RGMa-expressing cells. Isolectin B4 (IB4)-and RGMa-positive cells were detected in the epicenter area ( Fig. 2 J) , suggesting that RGMa is expressed in the microglia/macrophages at the lesion epicenter (Streit, 1990) . MOSP-and RGMa-positive cells were detected in the white matter adjacent to the epicenter area, demonstrating that RGMa is expressed in the oligodendrocytes in this area. We found that all the MOSP-expressing cells also expressed RGMa, whereas RGMa-positive and MOSP-negative cells were detected particularly around the lesioned site (Fig. 2 , K and L). The results of the double staining for IB4 and RGMa suggest that an increase of these cells is attributable to an increase in the number of RGMa-expressing microglia/macrophages in the epicenter area. We did not observe GFAP-and RGMa-positive or Tuj1-and RGMa-positive cells in the lesion epicenter or in the adjacent white matter (unpublished data).
The anti-RGMa antibody neutralizes the inhibitory effect of RGMa and CNS myelin
These results suggest that RGMa with its potent inhibitory activity of neurite outgrowth inhibits axonal regeneration after SCI and that blockage of it offers potential for enhanced recovery after SCI. We therefore investigated whether the anti-RGMa antibody could neutralize the inhibitory activity of RGMa in the coculture assay (Fig. 3, A and B ) and the soluble RGMa assay (Fig. 3, C and D) . In both assays, the addition of the anti-RGMa antibody but not the control IgG signifi cantly reversed the inhibitory effect of RGMa, demonstrating that the anti-RGMa antibody functions as a neutralizing antibody against RGMa in vitro.
As our data demonstrate that RGMa is expressed by the CNS myelin, the anti-RGMa antibody may reverse the inhibitory activity of the CNS myelin on neurite outgrowth. To test this hypothesis, we cultured neurons on poly-l-lysine (PLL)-coated or PLL + myelin-coated chamber slides for 24 h in the presence or absence of the anti-RGMa antibody (Fig. 3, E and F) . The inhibitory activity of myelin on neurite outgrowth was partially blocked by the anti-RGMa antibody. We next performed immunodepletion of the CNS myelin with anti-RGMa antibody and cultured neurons on depleted myelin-coated chamber slides for 24 h. Immunodepletion (Fig. 3 G) partially abolished the inhibitory response (Fig. 3, H and I) . Thus, myelinderived inhibitors except RGMa contribute signifi cantly to the inhibitory response of CNS myelin.
RGMa neutralization leads to functional improvement
We then assessed whether endogenous RGMa acts as an inhibitor of axon regeneration in the injured CNS. We transected two thirds of the dorsal region of rat spinal cords at the vertebral level Th9/10 (lesions 1.8 mm in depth). This resulted in the transection of the main as well as the lateral corticospinal tracts (CSTs). The neutralizing antibodies to RGMa or the control rabbit IgGs were delivered via osmotic minipumps with catheters placed intrathecally near the thoracic injury site. There was no signifi cant difference between the lesion depths in the control and treated groups (Fig. 4 A) . The locomotor performance of the animals was monitored over a period of 9 wk after injury. The sham-operated rats (Fig. 4 B) achieved full scores according to the Basso-Beattie-Bresnahan locomotor rating scale (BBB; Basso et al., 1995) . All the spinally injured rats became almost completely paraplegic on the fi rst day after the injury (Fig. 4 B) and then gradually displayed partial recovery of locomotor behavior as assessed by the BBB scores. There was no difference in the BBB scores of the anti-RGMa antibody-and control antibody-treated rats up to 4 wk after SCI. In fact, the locomotor performance from 6-9 wk after the surgery was signifi cantly better in rats treated with the anti-RGMa antibody than in those treated with the control antibody. On average, rats treated with the control antibody attained a BBB score of 10.6, whereas those treated with the anti-RGMa antibody achieved a BBB score of 14.9 at 9 wk after the surgery. Thus, the antiRGMa antibody is effective in treating rats with SCI.
RGMa inhibition induces long-distance growth of injured fi ber tracts
The integrity of the dorsal CST in some previously tested rats was assessed by injecting biotin-dextran amine (BDA) into the bilateral sensory-motor cortices. For a group of animals (eight control and six anti-RGMa antibody-treated rats), blocks extending 5 mm rostral and 5 mm caudal to the center of the injury were sectioned in the sagittal plane (Figs. 5 and 6). The far rostral as well as the far caudal segments were sectioned in the transverse plane (Fig. 7) . For another group (three control and (A) Quantifi cation of the lesion depth revealed that there was no statistically signifi cant difference between the control and anti-RGMa antibodytreated animals. The signifi cance was determined by t test. Mean ± SEM of nine anti-RGMa antibody-treated and 11 control rats. (B) The BBB score was determined at the indicated times after thoracic dorsal hemisection in the anti-RGMa antibody-treated, control antibody-treated, and shamoperated rats. Mean ± SEM of 9, 11, and 5 rats for each group, respectively. The anti-RGMa antibody-treated group is statistically different from the control group, as indicated. *, P < 0.05 compared with the control; **, P < 0.06 compared with the control.
three anti-RGMa antibody-treated rats), the spinal cords were sectioned in the transverse plane (Fig. 7) .
Samples from the injured rats treated with the anti-RGMa antibody exhibit a completely different pattern of labeling ( Proximal to the lesion, the main CST appears as a tight bundle of fi bers, with the traced fi bers neither entering nor growing beyond the lesion site in the control rats (Fig. 5, A, C , and E). This baseline pattern refl ects that axonal regeneration does not normally occur in the CNS. In contrast, numerous ectopic fi bers sprouting from the labeled CST were observed both rostral and caudal to the lesion site in rats that were treated with the antiRGMa antibody (Fig. 5, B and D) . The longitudinal sections across the lesion site reveal lower retraction of the main CST bundles and a higher number of collateral CST sprouts in rats treated with the neutralizing antibody (Fig. 5, A and B; and Fig. 6 A) . Regenerating fi bers with typical irregular meandering growth patterns were frequently observed in the tissue bridges at the level of the lesion in rats treated with anti-RGMa antibody (Figs. 5, D and F; and Fig. S5, A and B) . These regenerating fi bers extended into the lesion scar, the gray matter caudal to the lesion, and along cysts (Fig. 5, F and H; and Fig. S3 ).
Notably, many axons traversed the lesion tissue, thereby growing either around cavities or within the lesion epicenter, whereas no BDA-traced CST fi bers could be detected in the control rats (Fig. 5 E) . Bundles of axons extended through the lesion tissue and numerous labeled fi bers were observed caudal to the lesion sites in the anti-RGMa antibody-treated rats (Figs. 5, and Figs. S3 and S5) . In only one rat treated with the anti-RGMa antibody, however, did we not detect BDA-positive fi ber in the scar tissue or caudal to the lesion site. Serial microscopic images (Fig. 5, I -R and Fig. S4 , A-J) and camera lucida drawings of all the BDA-labeled fi bers (Fig. S4 , K and L) summarize the pattern of CST fi ber growth in the rostral-caudal region of the injury. A few undamaged ventral fi bers were illustrated in both cases.
We then reconstructed the serial sections of the injured spinal cords using all the 70-80 serial longitudinal sections per rat and estimated the number of the labeled fi bers. In comparison with the number of labeled fi bers observed 4 mm rostral to the lesioned site, >20% of the labeled fi bers were seen in the caudal spinal cord of rats treated with the anti-RGMa antibody. However, only a small percentage of the fi bers (1% at 1 mm caudal to the injury site) were seen in the control antibodytreated rats (Fig. 6 B) . Most of these fi bers follow branched and tortuous courses, instead of a linear trajectory (Fig. 5 H; Fig. S3 , B and C; Fig. S5 , B, D, F, and H; and Video 1, available at http://www.jcb.org/cgi/content/full/jcb.200508143/DC1). At the caudal-most part of the regenerating fi bers, we observed branches sprouting from the main tract ( Fig. 5 G and Fig. S5 F) .
We obtained cross-sections of the spinal cord and performed a quantitative analysis of the distribution of the axons to exclude the possibility of axon sparing in the anti-RGMa antibody-treated rats. The total number of labeled fi bers 10 mm above the lesion was almost identical between the anti-RGMa and control antibody-treated rats (Fig. 7, A, B , and I), indicating that the extent of BDA uptake was the same between the control and anti-RGMa antibody-treated rats. A thorough serial section reconstruction of the lesion site enabled us to conclude that there was no labeled CST axon that extended past the lesion in the normal locations of the dorsal CST in any of the rats (Fig. 7, C and D) . In rats treated with the anti-RGMa antibody, however, BDA-positive fi bers with tortuous appearance were detected in the scar tissue developing at the lesion site (Fig. 7, D and E). At 10 mm caudal to the lesion site, the sprouting axons extended through the gray matter to a greater extent than in the white matter in rats treated with the anti-RGMa antibody (Fig. 7 , F-H and J-L). Almost no fi bers were seen in the ventral part of the dorsal or dorsolateral column in the anti-RGMa antibody-treated rats as well as the control antibody-treated rats (Fig. 7, F (Fig. 7 J) were not different from those in the negative control (non-BDA-labeled rats; not depicted). There was a little nonspecifi c staining in the CST, which accounts for the few fi ber counts in the CST (Fig. 7 J) . These data strongly suggest that there were no spared CST axons, as axons that are spared and extend into the caudal segments should be present in their normal locations. Multiple fi bers with tortuous appearance and unusual branching were seen in the gray matter in injured animals treated with the anti-RGMa antibody (Fig. 7, G , H, J, and L). In only one rat treated with the anti-RGMa antibody, however, did we not detect BDA-positive fi ber at 1 mm caudal to the injury site. It should be noted that the labeling of the gray matter caudal to the lesion site might be due to sprouting from undamaged ventral fi bers. It is not possible to defi nitely determine longtract regeneration. Our fi ndings, however, met many of the criteria for identifying regenerated axons (Steward et al., 2003) and raise the possibility that anti-RGMa antibody treatment promotes regrowth of injured CST axons.
and G [insets] and J). The fi ber counts in the CST
Finally, we assessed whether the functional improvement is temporally correlated with the anatomical regeneration. We took consecutive sagittal sections of the spinal cords from anti-RGMa antibody-treated animals 3 and 5 wk after injury (n = 3 for each group). Fig. 8 shows representative pictures of BDA-labeled CST fi bers in the control (Fig. 8 , A and C) and anti-RGMa antibodytreated animals (Fig. 8, B and D) 5 wk after injury. In anti-RGMa antibody-treated animals, the regenerating fi bers extended into the lesion scar but did not extend into the caudal part of the spinal cord (Fig. 8, B and D) . In the control rats, there was no labeled CST axon that extended past the lesion (Fig. 8, A and C) . We reconstructed the injured spinal cords and assessed the number of the labeled fi bers (Fig. 8 E) . 3 wk after injury, there was no signifi cant difference between the fi ber counts at any distance from the lesion site in anti-RGMa antibody-and control IgG-treated rats (Fig. 8 E) . 5 wk after injury, a signifi cant number of BDApositive fi bers ‫%52ف(‬ as compared with the number observed 4 mm rostral to the lesioned site) were detected at the lesion epicenter in anti-RGM antibody-treated rats, whereas almost no fi bers were seen in the control rats. These results suggest that functional improvement is temporally correlated with anatomical regeneration/sprouting in animals treated with anti-RGMa.
Discussion
The failure of axon regeneration in the spinal cord is at least partly attributable to the growth inhibitory properties of the CNS white matter and the scar tissue developing at the lesion site. Several observations in this study established the notion that RGMa inhibits axon regeneration after SCI. RGMa inhibits neurite outgrowth by activating the RhoA-Rho kinase signaling pathway in vitro and is expressed by oligodendrocytes, myelin, and neurons in the adult rat CNS. After SCI, RGMa expression is induced in the oligodendrocytes and microglia/macrophages around the injury site. The anti-RGMa antibody, which blocks the inhibitory effect of RGMa and CNS myelin in vitro, enhances axonal regeneration/sprouting as well as functional recovery in vivo.
RhoA/Rho kinase and axon growth inhibition
Our data demonstrated that the inhibitory effect of RGM on the neurons is independent of the NgR and is mediated by the RhoARho kinase signaling pathway. This pathway is activated by three well-characterized myelin-associated inhibitors, Nogo, MAG, and OMgp, as well as CSPG, which are expressed both in the glial scar and in myelin (Mueller et al., 2005) . Current evidence indicates that a common crucial signaling event for these myelinderived inhibitors of axon growth is the activation of RhoA. P75 transduces the signal of the three myelin-derived inhibitors of axon regeneration by acting as a displacement factor that releases RhoA from Rho guanine dissociation inhibitor (Yamashita and Tohyama, 2003) , which functions to maintain RhoA in an inactive state by sequestering it in the cytoplasm and inhibiting the formation of active RhoGTP. Importantly, Dubreuil et al. (2003) demonstrated that SCI induces RhoA activation in both glial cells and neurons in vivo. They also found that immediate RhoA activation after SCI is p75 dependent but, thereafter, RhoA could be activated in a p75-independent manner. These observations suggest the presence of other molecules that activate RhoA; this is consistent with our fi ndings that RGMa activates RhoA and that its expression is induced around the injury site.
Expression of RGMa in the CNS
An immunohistochemical study of the normal spinal cord shows that RGMa is expressed by neurons and oligodendrocytes. This expression pattern in the spinal cord is similar to that of Nogo or OMgp (Hunt et al., 2002) . In the injured spinal cord, however, the expression of RGMa around the lesion site is upregulated; RGMa is expressed in the microglia/macrophages and oligodendrocytes at the injury site. Our recent report demonstrates that, after SCI, RGMa is expressed by neurons, ballooned neurite fi bers/retraction bulbs, oligodendrocytes, smooth muscle/endothelial cells, microglia/macrophages, leucocytes infi ltrating the lesion, and with maturation of the lesion, cellular components (e.g., fi broblastoid cells) and extracellular components of the developing scar tissue (cicatrix; Schwab et al., 2005a) . In the human brain, a massive up-regulation of RGMa was observed at the lesioned or damaged site after focal cerebral ischemia or traumatic brain injury; RGMa was also present in the scar tissue (Schwab et al., 2005b) . These observations suggest the important role of RGMa as an inhibitor of axon regeneration in the injured adult mammalian CNS.
Functional recovery and axon regeneration after SCI
We observed an enhanced locomotor recovery by treatment with the anti-RGMa antibody after SCI. A delayed improvement in locomotor recovery in the anti-RGMa antibody-treated rats might be related to the time course of RGMa expression, which was up-regulated after SCI.
We observed massive fi ber growth by anti-RGMa antibody treatment in vivo, whereas the injured axons exhibited little, if any, sprouting in the spinal cord without the treatment. To exclude the possibility that the labeled fi bers seen in the caudal portion of the spinal cord are spared axons, we performed thorough reconstructions of the lesioned spinal cord by taking crosssections (Fig. 7) . Multiple fi bers with tortuous appearance and unusual branching patterns extended through the gray matter to a greater extent than in the white matter in the caudal portion of the spinal cords of rats treated with the anti-RGMa antibody. The labeled fi bers in the gray matter 10 mm caudal to the lesion site are not collaterals of the dorsal CST, as most of the gray matter collaterals of the CST extend in the transverse plane and do not extend for long distances longitudinally through the gray matter (Steward et al., 2003) . In fact, analysis of the serial sections of the lesion site from each rat revealed that there was no labeled CST axon that extended past the lesion in the normal locations of the dorsal CST. These fi ndings strongly support our notion that the anti-RGMa antibody promotes regeneration and/or sprouting of injured CST fi bers (Steward et al., 2003) . However, it is not possible to defi nitely determine long-tract regeneration. It is possible that the labeling in the gray matter caudal to the lesion site might be due to the sprouting from the undamaged ventral fi bers. Evidence suggests that the ventral CST axons collaterally sprout into the gray matter after injury to the dorsal CST (Weidner et al., 2001 ). Treatment with a high dose of the Rho kinase inhibitor (Y29632), which enhanced functional recovery, induced an increase in the CST profi les in the gray matter distal to the site of injury; this is indicative of collateral sprouting from the ventral spared CST axons (Chan et al., 2005) . It is possible to induce the local reorganization of the central pattern generator circuitry, including sprouting from the undamaged ventral fi bers, followed by enhanced functional recovery after SCI in anti-RGMa-treated animals.
Mutant mice lacking RGMa may also be useful in determining whether deletion of RGMa enhances the regeneration ability. However, as ‫%05ف‬ of the mRGMa mutant mice show defects in cephalic neural tube closure (Niederkofl er et al., 2004) , conditional knockout mice would be needed to address this issue without considering the effect of RGMa in embryonic development.
Although there is some controversy concerning experiments with targeted gene disruption of the myelin-associated inhibitors, treatments with some neutralizing agents have shown effi cacy in promoting regeneration in animal SCI. Similar to our fi ndings in anti-RGMa antibody treatment, treatment with the anti-Nogo A antibody induces regeneration after rat SCI (Bregman et al., 1995) . A peptide antagonist, NEP1-40, which competes for binding of Nogo-66 to the NgR, has also shown signifi cant effi cacy in terms of promoting regeneration in SCI models (GrandPre et al., 2002; Teng and Tang, 2005) . Thus, neutralizing agents including the anti-RGMa antibody may have the potential for clinical applications against SCI (Teng and Tang, 2005) .
Signaling mechanism of RGMa
Neogenin is a high-affi nity receptor for RGM, mediating its repulsive activity for retinal axons (Rajagopalan et al., 2004) . It was recently reported that RGMa mediates BMP signaling by acting as a coreceptor via Smad 1, 5, and 8 and up-regulates the endogenous inhibitor of differentiation (Id1) protein (Babitt et al., 2005 ). An interaction of RGMa with neogenin along with BMP type I receptor or as a homophilic interaction by itself, as reported for RGMb (dragon; Samad et al., 2004) , might underlie its inhibitory activity toward the regeneration of CST fi bers. Higher magnifi cation of the boxed regions in A and B, showing regenerating fi bers, with typical irregular meandering growth patterns around the cysts at the lesion site (D) in rats treated with the anti-RGMa antibody but not in the corresponding regions of the control IgG-treated rats (C). In both the groups, no BDA-traced fi bers could be observed in the caudal part of the spinal cord 5 wk after injury. (E) Quantifi cation of the labeled CST fi bers in the anti-RGMa antibody-treated animals 3 wk (n = 3) and 5 wk (n = 3) after injury and in the control IgG-treated animals 3 wk (n = 3) and 5 wk (n = 3) after injury. All the 50-μm-thick serial parasagittal sections were evaluated. The x axis indicates specifi c locations along the rostrocaudal axis of the spinal cord. The y axis indicates the ratio of the number of BDA-labeled fi bers at the indicated site to those at 4 mm rostral to the lesion site. *, P < 0.05 compared with the control (5W). Bars: (A and B) 500 μm; (C and D) 100 μm.
A clarifi cation of the precise signaling cascade of the RGMa is expected to contribute to the development of more effective therapies for the treatment of adult mammalian CNS injuries.
In summary, our results demonstrate that RGMa is an important inhibitory molecule for successful neuroregeneration in vivo and suggest that its manipulation would be useful for the treatment of human spinal injuries.
Materials and methods
Plasmid constructs
Because the previous report (Monnier et al., 2002) has shown that native chick and functionally active RGM starts with residue 152, we created an HA-RGMa vector in pSecTag2-Hygro (Invitrogen) using the signal peptide of pSecTag2 fused to HA and residues 152-431 of rat RGMa (available from GenBank/EMBL/DDBJ, under accession no. XP_218791). FPC-1-MAG-Fc-and MAG-Fc-expressing CHO cells are gifts from M. Endo and K. Mizuno (Tohoku University, Sendai, Japan).
Generation of RGMa-CHO cells
Flp-in system (Invitrogen) was used to generate RGMa-expressing cells according to the manufacturer's recommendations. We generated an HARGMa fragment containing a signal peptide from pSecTag2 vector using two restriction endonucleases and ligated it into pcDNA5FRT (Invitrogen). This construct (pcDNA5FRT/Igκleader/HA/RGMa) and pOG44 were cotransfected into Flp-in CHO cells, and stable expressing cells were generated after growth in medium containing 500 μg/ml Hygromycin B (Invitrogen) for 2 wk. Expression of HA-RGMa was confi rmed by immunodetection using Western blots and immunocytochemistry. We also generated human RGMa-expressing cells and confi rmed that human RGMa, either membrane bound or diffusible, potently inhibits the neurite outgrowth of postnatal cerebellar granule neurons.
Neurite outgrowth assay
Cerebellar granule cells from rat pups at postnatal days 7-9 were dissociated by trypsinization (0.25% trypsin in PBS for 15 min at 37°C) followed by resuspension in serum-containing medium, trituration, and wash with PBS three times. Cultures were grown in a serum-free DME/F12 medium. For the coculture assay, neurons were plated on confl uent monolayers of either RGMa-CHO or control CHO cells in chamber slides (LabTek II; Nunc). For the soluble RGMa assay, confl uent monolayers of either RGMa-CHO or control CHO cells were incubated in serum-free DME/F12 medium with or without 2.5 U/ml PI-PLC (Sigma-Aldrich) at 37°C for 3 h. Those treated CHO cells were subjected to the coculture assay. After centrifugation of the culture media at 13,000 g for 10 min, the supernatants were collected to remove fl oating cells. A part of the supernatants was subjected to SDS-PAGE and Western blot analysis to estimate concentration of soluble RGMa with various amounts of the standards (recombinant RGM-A; R&D Systems). Estimated concentration of soluble RGMa was 1.37 (± 0.13 SEM) μg/ml. Neurons were plated in the conditioned media on PLL-coated chamber slides and were incubated for 12 or 24 h. Where indicated, 10 μM of Y27632 (Mitsubishi Pharmaceuticals) was added to the cultures. To inhibit the NgR, 1 μM of NEP(1-40) (Sigma-Aldrich) was added to the culture. For neutralizing antibody assay, anti-RGMa antibody or control rabbit IgG was added to the culture at the concentration of 10 μg/ml. For the neurite outgrowth assay on myelin, we performed myelin preparation from rat brain as described previously (Norton and Padulso, 1973) . 3 μg/well of the purifi ed myelin or the depleted myelin were used to coat PLL-coated eight-well chamber slides (Benson et al., 2005) . The cells were fi xed in 4% (wt/vol) paraformaldehyde and were immunostained with a monoclonal antibody recognizing TuJ1 (1:1,000; Covance). The length of the longest neurite for each β tubulin III-positive neuron was then determined.
Affi nity precipitation of GTP-RhoA Cells were lysed in 50 mM Tris, pH 7.5, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 500 mM NaCl, and 10 mM MgCl 2 , with leupeptin and aprotinin, each at 10 μg/ml. Cell lysates were clarifi ed by centrifugation at 13,000 g at 4°C for 10 min, and the supernatants were incubated with the 20 μg of GST-Rho binding domain of Rhotekin beads (Upstate Biotechnology) at 4°C for 45 min. The beads were washed four times with washing buffer (50 mM Tris, pH 7.5, containing 1% Triton X-100, 150 mM NaCl, 10 mM MgCl 2 , and 10 μg/ml each of leupeptin and aprotinin). Bound Rho proteins were detected by Western blotting using a monoclonal antibody against RhoA (Santa Cruz Biotechnology, Inc.).
Immunodepletion of RGMa
To examine the remaining effect of myelin-derived inhibitors except RGMa on neurite outgrowth, we subjected the sample to four rounds of immunodepletion (McKerracher et al., 1994) . The purifi ed myelin was extracted with 20% octylglucoside salt (Dojindo). The extract was centrifuged at 40,000 g for 60 min, and the supernatant was incubated with the 20 μg of anti-RGMa antibody overnight at 4°C. 50 μg of protein A beads were added for 3 h with rotation and centrifuged, and the supernatant was subjected to three repeat treatments. The fi nal depleted samples and the protein A beads were subjected to SDS-PAGE and Western blot analysis, and bioassays were performed as described (see Neurite outgrowth assay).
Western blot analysis CHO cells, cerebellar granule neurons, or adult rat spinal cords were lysed in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10% glycerol, and 0.5% Brij-58 (Sigma-Aldrich), including protease inhibitor cocktail tablets (Roche Diagnostics). The lysates were clarifi ed by centrifugation at 13,000 g at 4°C for 10 min, and the supernatants were collected and normalized for protein concentration. Equal amounts of protein were then boiled in sample buffer containing 12% β-mercaptoethanol for 5 min and subjected to SDS-PAGE. The conditioned media, purifi ed myelin, MAG-Fc, and CSPG (Chemicon) were also treated in the same manner except for the lysis buffer treatment. MAG-Fc was purifi ed from stable expressing cells (provided by K. Mizuno). The proteins were transferred onto polyvinylidene difl uoride membrane and incubated with 1 μg/ml of a polyclonal anti-RGMa antibody, a monoclonal anti-HA antibody (1:1,000; Sigma-Aldrich), a polyclonal anti-neogenin antibody (1:1,000; Santa Cruz Biotechnology, Inc.), or a polyclonal anti-actin antibody (1:1,000; Santa Cruz Biotechnology, Inc.). For detection, an ECL chemiluminescence system (GE Healthcare) and HRP-conjugated secondary antibodies (1:1,000; Cell Signaling Technology) were used.
Anti-rat RGMa antibody production
The domain important for functional activity in chick RGM is the COOHterminal 150-200 amino acids of the active RGM protein. A synthetic peptide (residues 309-322) was selected as immunogen to generate antirat RGMa rabbit antisera. The sequence of the peptide is specifi c to rat RGMa but has no similarity with RGMb or -c. Antisera were affi nity purifi ed and used at 1 μg/ml for immunohistochemistry and immunoblots and at 10 μg/ml for neutralizing antibody assay. To assess the specifi city of the anti-RGMa antibody, control and SCI sections were stained in the presence of the rat RGMa-specifi c peptide (residues 309-322; Fig. S2 ). An additional control experiment was done by leaving out the primary antibody. These experiments confi rmed the specifi city of the anti-RGMa antibody.
Surgical procedure
Anesthetized (sodium pentobarbital, 40 mg/kg) female Wistar rats (200-250 g) received a laminectomy at vertebral level T9/10, and the spinal cord was exposed. A number 11 blade was used to cut the dorsal part of the spinal cord at a depth of 1.8 mm. Histologic examination has revealed that these lesions sever all dorsal CST fi bers in the dorsal funiculus as well as the lateral CST and extend past the central canal in all animals. For neutralizing antibody assay in animal model, immediately after the spinal cord hemisection, rats were fi tted with an osmotic minipump (200 μl solution, 0.5 μl/h, 14-d delivery; Alzet pump model 2002 [Durect Co.] ) fi lled with control rabbit IgG (17 animals, 22.3 μg/kg/day over 2 wk; SigmaAldrich) or anti-RGMa antibody (15 animals, 22.3 μg/kg/day over 2 wk). The minipump was placed under the skin on the animal's back, and a silastic tube connected to the outlet of the minipump was placed under the dura at the spinal cord hemisection site with the tip lying immediately rostral to the injury site. The tube was sutured to the spinous process just caudal to the laminectomy to anchor it in place. Afterward, the muscle and skin layers were sutured. The bladder was expressed by manual abdominal pressure at least twice a day until bladder function was restored. Sham-operated rats (fi ve animals) received a laminectomy at vertebral level T9/10, and the spinal cords were exposed. The muscle and skin layers were then sutured.
Tissue preparation and immunohistochemistry
For immunohistochemistry, fresh frozen tissues were obtained from an uninjured spinal cord and from ones at 6 h and 1, 3, and 7 d after injury.
After deep anesthesia with diethyl ether, the rats were decapitated and the spinal cords dissected out, embedded in Tissue Tek OCT, and immediately frozen on dry ice at −80°C. Series of parasagittal sections as well as crosssections were cut at 18 or 50 μm on a cryostat and mounted on APS coating Superfrost-Plus slides (Matsunami). The sections were fi xed in 4% (wt/vol) paraformaldehyde for 1 h at room temperature, washed three times with PBS, and blocked in PBS containing 5% goat serum and 0.1% Triton X-100 for 1 h at room temperature. The sections were incubated with primary antibodies overnight at 4°C and washed three times with PBS, followed by incubation with fl uorescein-conjugated secondary antibodies (1:1,000; Invitrogen) for 1 h at room temperature. 1 μg/ml of polyclonal anti-RGMa antibody, monoclonal anti-GFAP (1:1,000; Sigma-Aldrich), monoclonal anti-MOSP (1:500; Chemicon), or monoclonal antibody recognizing TuJ1 (1:1,000; Covance) was used as the primary antibody. For double labeling of IB4 from Griffonia simplicifolia (1:100; Vector Laboratories) and RGMa, the animals were killed by perfusion with PBS followed by 4% paraformaldehyde. The spinal cords were dissected, postfi xed, and heated. Samples were examined under a confocal laser-scanning microscope (Carl Zeiss MicroImaging, Inc.) with 4×, 10×, 20×, 40×, and 63× objectives.
Anterograde labeling of the CST 1 wk (three control and three anti-RGMa antibody-treated rats), 3 wk (three control and three anti-RGMa antibody-treated rats), or 8 wk (11 control and 9 anti-RGMa antibody-treated rats) after injury, descending CST fi bers were labeled with BDA (10% in saline, 3.5 μl per cortex, MW 10,000; Invitrogen) injected under anesthesia at the left and the right motor cortices (coordinates: 2 mm posterior to bregma, 2 mm lateral to bregma, 1.5 mm depth). For each injection, 0.25 μl of BDA was delivered for a period of 30 s via a 15-20-μm inner diameter glass capillary attached to a microliter syringe (ITO). In total, we examined and compared the regenerative responses of 17 control and 15 anti-RGMa antibody-treated rats after SCI. 14 d after BDA injection, the animals were killed by perfusion with PBS followed by 4% paraformaldehyde. The spinal cords were dissected, postfi xed overnight in the same fi xatives, and cryopreserved in 30% sucrose in PBS. The spinal cord 5 mm rostral and 5 mm caudal to the lesion site (10 mm long) was embedded in Tissue Tek OCT. These blocks were sectioned in the sagittal plane (50 μm) or in the transverse plane, retaining each section. In both cases, transverse sections were also collected from the spinal cord >5 mm rostral and caudal to the injury site (17 control and 15 anti-RGMa antibody-treated rats). Sections were blocked in PBS with 0.5% BSA for 1 h and then incubated for 1 d with Alexa Fluor 488-conjugated streptavidin (1:400; Invitrogen) in PBS with 0.15% BSA.
Quantifi cation
To reconstruct serial parasagittal sections completely, all serial 50-μm-thick sections ‫08-07ف(‬ sections per animal; eight control and six anti-RGMa antibody-treated rats in Fig. 6 B, six control and six anti-RGMa antibodytreated rats in Fig. 8 E) were evaluated. On each section, the number of intersections of BDA-labeled fi bers with a dorsoventral line was counted from 4 mm above to 4 mm below the lesion site. Axon number was calculated as a percentage of the fi bers seen 4 mm above the lesion, where the CST was intact. The distance beyond the epicenter of the lesion was scored as positive and otherwise as negative distance.
The distance from the end of the main CST bundles to the lesion epicenter was measured for each animal for quantifi cation of the retraction of CST fi bers. The distance beyond the epicenter of the lesion was scored as positive and otherwise as negative distance.
To exclude the possibility of axon sparing in the anti-RGMa antibody-treated rats, we took thorough serial cross-sections of the spinal cord and performed quantitative analysis of the distribution of the axons (11 control and 9 anti-RGMa antibody-treated rats). Degrees of BDA uptake were assessed by counting the total number of fi bers in the cross-section 10 mm rostral to the lesioned site. For quantifi cation of the number of labeled corticospinal axons 10 mm caudal to the lesion site, the number of the labeled fi bers was measured for each animal in the gray matter, the dorsal CST area (normal locations of the dorsal CST), or the white matter except the dorsal CST area, divided by the number of labeled corticospinal axons 10 mm above the lesion.
For camera lucida drawing, all consecutive parasagittal sections from 4 mm above to 4 mm below the injury site or transverse sections around 10 mm caudal the lesion site were imaged, and BDA-positive CST axons were traced.
Behavioral testing
Behavioral recovery was assessed for 9 wk after injury in an open fi eld environment by the BBB. Uninjured and sham-operated rats (n = 5) achieved full scores. Quantifi cation was performed in a blinded manner by two (the fi rst group; eight control and six anti-RGMa antibody-treated rats) or three (the second group; three control and three anti-RGMa antibody-treated rats) observers. The difference of judged counts among the observers was within 1 point on the BBB scoring scale. Fig. S1 demonstrates that cerebellar granule neurons express neogenin. Fig. S2 shows specifi city of the anti-RGMa antibody. Fig. S3 shows regenerated CST axons with the anti-RGMa antibody treatment. Fig. S4 displays serial microscopic images of a control IgG-treated rat and reconstruction of the lesioned spinal cords treated with control IgG or the anti-RGMa antibody. Fig. S5 shows injured spinal cords of four animals with anti-RGMa antibody treatment. Video 1 shows regenerated CST axons with the antiRGMa antibody treatment. Online supplemental material is available at http://www.jcb.org/cgi/content/full/jcb.200508143/DC1.
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